SOUTH SAN FRANCISCO, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology today issued the following statement: “It is with great sadness that we announce that Lewis (Lew) J. Shuster, a member of the company’s board of directors, died last week due to recently diagnosed, late-stage pancreatic cancer. The entire Principia team mourns the loss of Lew and he will be dearly missed. Lew was a tremendously thoughtful and insightful board member, but more importantly, he was a kind and generous individual who brought a great deal of passion and energy to our industry and to the pursuit of our mission. On behalf of our board of directors, management team and employees, we extend our deep sympathies to Lew’s family.”
Mr. Shuster has been a strategic and operating advisor to life sciences companies since founding Shuster Capital in 2002. Mr. Shuster dedicated himself to the life sciences industry for more than three decades, and had executive positions at companies including Kemia, Invitrogen, Pharmacopeia and Human Genome Sciences. Mr. Shuster gave generously of his time while serving as a director of over a dozen life sciences companies. Most recently, in addition to Principia, Mr. Shuster’s board memberships included Active Motif, Cleave Biosciences, TissueNetix and Turning Point Therapeutics. Mr. Shuster received a B.A. in economics from Swarthmore College and an M.B.A. from Stanford University Graduate School of Business.
About Principia Biopharma
Principia is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia’s proprietary Tailored Covalency® platform enables the Company to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics, yet maintain the convenience of a pill. For more information, please visit www.principiabio.com
Christopher Chai, CFO